The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in Germany

被引:44
作者
McBride, Doreen [1 ]
Mattenklotz, Anna M. [1 ]
Willich, Stefan N. [1 ]
Brueggenjuergen, Bernd [1 ]
机构
[1] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-10098 Berlin, Germany
关键词
cardiovascular disease; cost-measurement; Germany; treatment costs; STROKE PREVENTION; RISK-FACTORS; ELECTRICAL CARDIOVERSION; ACC/AHA/ESC GUIDELINES; ANTITHROMBOTIC THERAPY; RHYTHM MANAGEMENT; ANTICOAGULATION; PREVALENCE; QUALITY; IBUTILIDE;
D O I
10.1111/j.1524-4733.2008.00416.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Atrial fibrillation (AF) is an increasing burden on health-care systems because of an aging population. This study aimed to estimate health-care resource use and costs of treating AF in Germany. A 6-month multicenter prospective observational cohort study with additional 3-month retrospective clinical data collection was performed in physician practices. AF-related resource use was documented by 3-month retrospective and 6-month prospective clinical data from physician charts and prospectively by patient questionnaires at 3 and 6 months. Cost calculation was from the health-care payer perspective. A total of 361 patients (mean age 71 +/- 9 years, 61% male) were recruited from 45 physician practices. Of 311 (86.1%) patients with complete data, 75% had persistent AF; oral anticoagulation and/or aspirin were prescribed in 98%. A rhythm-control strategy was applied in 27%, rate control in 58%, and 15% received neither antiarrhythmic medication nor cardioversion. A higher proportion of rhythm-control patients had paroxysmal AF (P < 0.001). Mean annual AF-related per-patient cost was 827 Euro +/- 1476 (median 386 Euro). 50% of total costs were incurred by 11% of patients, driven by AF-related hospitalizations (44%). Antiarrhythmics and stroke prophylaxis accounted for 20% and 15% of expenditures, respectively. Mean annualized costs were higher for rhythm-control patients than for rate-control patients or those without antiarrhythmic treatment (1572 vs. 780 vs. 544 Euro, P < 0.001). This evaluation provides an overview of current treatment modalities and cost of AF management in Germany. Efforts to reduce the economic burden of AF should focus on avoidance of AF hospital admissions and optimization of stroke prevention and rhythm control.
引用
收藏
页码:293 / 301
页数:9
相关论文
共 46 条
[1]  
[Anonymous], 2001, CIRCULATION, V104, P2118
[2]   INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY [J].
BENJAMIN, EJ ;
LEVY, D ;
VAZIRI, SM ;
DAGOSTINO, RB ;
BELANGER, AJ ;
WOLF, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (11) :840-844
[3]   The impact of atrial fibrillation on the cost of stroke:: The Berlin acute stroke study [J].
Brueggenjuergen, Bernd ;
Rossnagel, Karin ;
Roll, Stephanie ;
Andersson, Fredrik L. ;
Selim, Dagmar ;
Mueller-Nordhorn, Jacqueline ;
Nolte, Christian H. ;
Jungehuelsing, Gerhard J. ;
Villringer, Arno ;
Willich, Stefan N. .
VALUE IN HEALTH, 2007, 10 (02) :137-143
[4]   Why do patients with atrial fibrillation not receive warfarin? [J].
Bungard, TJ ;
Ghali, WA ;
Teo, KK ;
McAlister, FA ;
Tsuyuki, RT .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) :41-46
[5]   Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation [J].
Chan, Paul S. ;
Vijan, Sandeep ;
Morady, Fred ;
Oral, Hakan .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (12) :2513-2520
[6]  
Choi Bernard K C, 2002, Chronic Dis Can, V23, P47
[7]   Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation [J].
Coleman, CI ;
Kalus, JS ;
White, CM ;
Spencer, AP ;
Tsikouris, JP ;
Chung, JO ;
Kenyon, KW ;
Ziska, M ;
Kluger, J ;
Reddy, P .
PHARMACOECONOMICS, 2004, 22 (13) :877-883
[8]   Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States [J].
Coyne, Karin S. ;
Paramore, Clark ;
Grandy, Susan ;
Mercader, Marco ;
Reynolds, Matthew ;
Zimetbaum, Peter .
VALUE IN HEALTH, 2006, 9 (05) :348-356
[9]   Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation [J].
de Paola, AAV ;
Figueiredo, E ;
Sesso, R ;
Veloso, HH ;
Nascimento, LOT .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2003, 88 (2-3) :157-166
[10]   Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study [J].
Deplanque, D ;
Leys, D ;
Parnetti, L ;
Schmidt, R ;
Ferro, J ;
De Reuck, J ;
Mas, JL ;
Gallai, V .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (06) :798-806